Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 15/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 15/20 | 0.71 |
| ▸ | NPC1 | O15118 | 14/20 | 0.71 |
| ▸ | MAPT | P10636 | 11/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.71 |
| ▸ | LMNA | P02545 | 6/20 | 0.71 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.71 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.71 |
| ▸ | RELA | Q04206 | 3/20 | 0.71 |
| ▸ | POLB | P06746 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.69 |
| ▸ | MEN1 | O00255 | 9/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.67 |
| ▸ | CLK1 | P49759 | 2/20 | 0.67 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 3/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7231250 | 0.83 | MAPT (0.76) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL11137540 | 0.78 | RRM1 (0.70) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL16603988 | 0.78 | RAB9A (0.68) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL2753606 | 0.78 | MAPT (0.82) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL4787032 | 0.77 | SMN1; SMN2 (0.66) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL12297528 | 0.77 | SMN1; SMN2 (0.93) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL12298034 | 0.77 | SMN1; SMN2 (0.72) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL4787782 | 0.77 | RAB9A (0.59) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL4787776 | 0.77 | RAB9A (0.59) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL11138234 | 0.76 | AMY1A (0.59) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-10463611-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2019-11-05 | — | — | US | disclosed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20140154313-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2014-06-05 | — | — | US | disclosed |
| EP-2717860-A1 | CONTROLLED ABSORPTION WATER-SOLUBLE PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND FORMULATION FOR ONCE-DAILY ADMINISTRATION | STI Pharma, LLC (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8454582-B2 | Methods and devices for the treatment of ocular conditions | SURMODICS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| WO-2002045693-A1 | PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX | ALTANA PHARMA AG (DE) | 2002-06-13 | — | — | WO | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
| US-5847150-A | Solid phase and combinatorial synthesis of substituted 2-methylene-2, 3-dihydrothiazoles and of arrays of substituted 2-methylene-2, 3-dihydrothiazoles | NOVO NORDISK A/S (DK) | 1998-12-08 | — | — | US | disclosed |
| WO-1997040030-A1 | SOLID PHASE AND COMBINATORIAL SYNTHESIS OF SUBSTITUTED 2-METHYLENE-2,3-DIHYDROTHIAZOLES AND OF ARRAYS OF SUBSTITUTED 2-METHYLENE-2,3-DIHYDROTHIAZOLES | NOVO NORDISK A/S (DK) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | RAB9A 1715/4885SMN1; SMN2 1978/4885NPC1 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.